Immunovant, Inc. (NASDAQ:IMVT) is considered one of the best short squeeze stocks to buy now, with Oppenheimer reaffirming an Outperform rating and a price target of $54 after fiscal second-quarter results. The company reported earnings per share of -$0.73, slightly missing the consensus estimate of -$0.71, but maintains a strong financial position with $4.4 billion in cash and no debt. Immunovant is focused on developing innovative therapies for autoimmune diseases, with upcoming results from studies on lupus, rheumatoid arthritis, and two autoimmune conditions. The company is also testing a second drug candidate, batoclimab, in mid-late-stage trials.

Read more at Yahoo Finance: Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings